Healthy adults
Conditions
Interventions
Consumption of the test food (a package/day) to the subjects for 12 weeks.
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy male/female subjects ranging in age from 20 to 64, at the moment of giving informed consent to partake in this trial. (2) Subjects who can give informed consent to take part in this trial after being provided with an explanation of our experimental protocol detail.
Exclusion criteria
Exclusion criteria: (1) Subjects who take steadily in anthocyanin-rich health-specific/functional/supplementary/health foods, and will have any difficulty in giving up taking them after the consent. (2) Subjects who have taken some kind of medicine, and have any difficulty in refraining from taking them during this trial. (3) Subjects with excessive alcohol intake. (4) Subjects with current and/or previous medical history of serious diseases in heart, liver, kidney and/or digestive organs. (5) Pregnant, lactating women, and possibly pregnant ones during this trial. (6) Subjects with drug and/or food allergy. (7) Subjects who are now under other clinical trials with some kind of medicine/food, or partook in those within four weeks before this trial, or planning to join those after the consent. (8) Subjects who donated over 200 mL of their blood and/or blood components within a month to this trial. (9) Males who donated their whole blood (400 mL) within the last three months to this trial. (10) Females who donated their whole blood (400 mL) within the last four months to this trial. (11) Males who will be collected in total of their blood (1200 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial. (12) Females who will be collected in total of their blood (800 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial. (13) Others who have been determined as ineligible for participation in this trial, according to the principal/sub investigator's opinions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of some kind of adverse event and/or side effect, and changes in clinical examination values. | — |
Countries
Japan
Contacts
Public ContactMasanori Numa
CPCC Company Limited Clinical Planning Department
Outcome results
None listed